Cytek Biosciences (CTKB) Common Equity (2020 - 2026)

Cytek Biosciences has reported Common Equity for 7 years, with the latest figure at $327.6 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 13.69% year-over-year to $327.6 million; the trailing twelve-month figure through Mar 2026 stood at $327.6 million (down 13.69% YoY), and the FY2025 full-year result was $341.7 million, down 13.64% from the prior year.
• Common Equity for Q1 2026 stood at $327.6 million, down from $341.7 million in the prior quarter.
• The five-year high for Common Equity was $425.5 million in Q4 2022, with the low at $327.6 million in Q1 2026.
• Historically, Common Equity has averaged $393.2 million across 5 years, with a median of $393.1 million in 2023.
• Annual changes were most pronounced in 2022 — Common Equity jumped 40644.2% — and 2026, when it fell 13.69%.
• Cytek Biosciences' Common Equity stood at $425.5 million in 2022, then decreased by 7.63% to $393.1 million in 2023, then grew by 0.68% to $395.7 million in 2024, then dropped by 13.64% to $341.7 million in 2025, then fell by 4.12% to $327.6 million in 2026.
• The last three Common Equity figures came in at $327.6 million (Q1 2026), $341.7 million (Q4 2025), and $378.6 million (Q3 2025), per Business Quant data.